Cargando…

High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes

OBJECTIVE: Maturity-onset diabetes of the young (MODY) as a result of mutations in hepatocyte nuclear factor 1-α (HNF1A) is often misdiagnosed as type 1 diabetes or type 2 diabetes. Recent work has shown that high-sensitivity C-reactive protein (hs-CRP) levels are lower in HNF1A-MODY than type 1 dia...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDonald, Tim J., Shields, Beverley M., Lawry, Jane, Owen, Katharine R., Gloyn, Anna L., Ellard, Sian, Hattersley, Andrew T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142017/ https://www.ncbi.nlm.nih.gov/pubmed/21700917 http://dx.doi.org/10.2337/dc11-0323

Ejemplares similares

Response to Comment on: McDonald et al. High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care 2011;34:1860–1862
por: McDonald, Tim J., et al.
Publicado: (2011)

Assessment of the HNF1B Score as a Tool to Select Patients for HNF1B Genetic Testing
por: Clissold, Rhian, et al.
Publicado: (2015)

Cystatin C is not a good candidate biomarker for HNF1A-MODY
por: Nowak, Natalia, et al.
Publicado: (2012)

Comment on: McDonald et al. High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care 2011;34:1860–1862
por: Blanco, Jesús, et al.
Publicado: (2011)

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin
por: Shepherd, Maggie H., et al.
Publicado: (2018)

Biomarkers: Tools for Discriminating MODY from Other Diabetic Subtypes
por: Firdous, Parveena, et al.
Publicado: (2022)

Association of birthweight and penetrance of diabetes in individuals with HNF4A-MODY: a cohort study
por: Locke, Jonathan M., et al.
Publicado: (2021)

South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people
por: Misra, Shivani, et al.
Publicado: (2016)

The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes
por: Shields, B. M., et al.
Publicado: (2012)

Variants influencing age at diagnosis of HNF1A-MODY
por: Ludwig-Słomczyńska, Agnieszka H., et al.
Publicado: (2022)

Syndromic monogenic diabetes genes should be tested in patients with a clinical suspicion of MODY
por: Colclough, Kevin, et al.
Publicado: (2022)

Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts
por: Mirshahi, Uyenlinh L, et al.
Publicado: (2022)

Double Heterozygous Mutations Involving Both HNF1A/MODY3 and HNF4A/MODY1 Genes: A case report
por: Forlani, Gabriele, et al.
Publicado: (2010)

Polygenic Risk Variants for Type 2 Diabetes Susceptibility Modify Age at Diagnosis in Monogenic HNF1A Diabetes
por: Lango Allen, Hana, et al.
Publicado: (2010)

The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotype
por: Hamilton, Alexander J, et al.
Publicado: (2014)

An Atypical HNF4A Mutation Which Does Not Conform to the Classic Presentation of HNF4A-MODY
por: Spiro, Andrew J., et al.
Publicado: (2018)

Circulating CD36 Is Reduced in HNF1A-MODY Carriers
por: Bacon, Siobhan, et al.
Publicado: (2013)

Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY
por: Oosterom, Nicole, et al.
Publicado: (2022)

Assessment of High-Sensitivity C-Reactive Protein Levels as Diagnostic Discriminator of Maturity-Onset Diabetes of the Young Due to HNF1A Mutations
por: Owen, Katharine R., et al.
Publicado: (2010)

Species-Specific Differences in the Expression of the HNF1A, HNF1B and HNF4A Genes
por: Harries, Lorna W., et al.
Publicado: (2009)

Circulating ghrelin level is higher in HNF1A–MODY and GCK–MODY than in polygenic forms of diabetes mellitus
por: Nowak, Natalia, et al.
Publicado: (2015)

Low Frequency Variants in the Exons Only Encoding Isoform A of HNF1A Do Not Contribute to Susceptibility to Type 2 Diabetes
por: Jafar-Mohammadi, Bahram, et al.
Publicado: (2009)

Granuloma annulare and necrobiosis lipoidica in a patient with HNF1A-MODY
por: Brandes, Gabriela Irene Garcia, et al.
Publicado: (2022)

Genetic and Clinical Characterization of Patients with HNF1B-Related MODY in Croatia
por: Baretić, Maja, et al.
Publicado: (2023)

Two Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration: Is it time to change the diagnostic criteria for MODY?
por: Pruhova, Stepanka, et al.
Publicado: (2013)

Differential regulation of serum microRNA expression by HNF1β and HNF1α transcription factors
por: Fendler, Wojciech, et al.
Publicado: (2016)

Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor 1β-associated renal disease and can be symptomatic
por: Clissold, Rhian L, et al.
Publicado: (2018)

Macrosomia and Hyperinsulinaemic Hypoglycaemia in Patients with Heterozygous Mutations in the HNF4A Gene
por: Pearson, Ewan R, et al.
Publicado: (2007)

Diabetes Susceptibility in the Canadian Oji-Cree Population Is Moderated by Abnormal mRNA Processing of HNF1A G319S Transcripts
por: Harries, Lorna W., et al.
Publicado: (2008)

Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-α/Hepatocyte Nuclear Factor 4-α Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes
por: Besser, Rachel E.J., et al.
Publicado: (2011)

Novel Use of GLP-1 Receptor Agonist Therapy in HNF4A-MODY
por: Broome, David T., et al.
Publicado: (2020)

Incidence of HNF1A and GCK MODY Variants in a South African Population
por: Matsha, Tandi E, et al.
Publicado: (2020)

Development of an exoglycosidase plate-based assay for detecting α1-3,4 fucosylation biomarker in individuals with HNF1A-MODY
por: Demus, Daniel, et al.
Publicado: (2021)

Homozygous Hypomorphic HNF1A Alleles Are a Novel Cause of Young-Onset Diabetes and Result in Sulfonylurea-Sensitive Diabetes
por: Misra, Shivani, et al.
Publicado: (2020)

OR34-06 Gliclazide Restores Appropriate Glucagon Suppression During OGTT In MODY3 & MODY1 Patients: Results Of The “Glucagon In MODY” Study
por: Spiliotis, Ioannis Ilias, et al.
Publicado: (2023)

Comparison of Glomerular Filtration Rate Estimation from Serum Creatinine and Cystatin C in HNF1A-MODY and Other Types of Diabetes
por: Szopa, Magdalena, et al.
Publicado: (2015)

Evaluation of Evidence for Pathogenicity Demonstrates That BLK, KLF11, and PAX4 Should Not Be Included in Diagnostic Testing for MODY
por: Laver, Thomas W., et al.
Publicado: (2022)

Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods
por: Demus, Daniel, et al.
Publicado: (2021)

MODY probability calculator for GCK and HNF1A screening in a multiethnic background population
por: Tarantino, Roberta Magalhães, et al.
Publicado: (2019)

Insights from basic adjunctive examinations of GCK‐MODY, HNF1A‐MODY, and type 2 diabetes: A systemic review and meta‐analysis
por: Liu, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4mm3opkg575flg6ra3ubb85ile